近日,东北证券发布研报,首次覆盖医渡科技,并给予“增持”评级。研报点评了医渡科技官微发布的3月动态。在科研领域,公司积极投身国家重点研发计划“前沿生物技术”专项,为慢病防治提供创新方案。行业交流层面,频繁亮相于北京卫视《专精特新研究院》、中关村论坛年会等重要平台,深度探讨AI医疗发展,分享数智科技成果。业务拓展方面,医渡科技成功打造首个肝癌专科“AI医生”,并与多地医院开展深度合作,推进大模型智能...
Source LinkDisclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.